Novo Nordisk (NVO) is set to roll out its highly popular weight-loss drug Wegovy in Asia, marking the medicine’s first foray into the continent.
Wegovy, also known as semaglutide, is slated to launch in Japan on Feb. 22, 2024.
The drug will be available at a monthly cost of 7,504 Japanese yen ($50.15) for a 0.25-milligram starter dose and 42,960 yen for a 2.4 mg dose to patients who have a body mass index (BMI) above 35, or a BMI above 27 for patients with two or more obesity-related co-morbidities, Novo (NVO) said.
The Danish company has been pushing ahead with launches of its highly popular diabetes and weight-loss drugs despite struggling to keep up with demand in existing markets.
Earlier this month, the drugmaker announced a $6B investment to expand production capacity in its home country. The investment, which includes GLP-1 products, will increase Novo Nordisk’s (NVO) ability to meet future market demands.
